MSU-42011

SKU: orb1744034

Description

MSU-42011 is a potent, orally bioavailable RXR agonist that suppresses iNOS, SREBP, and p-ERK protein expression. It exhibits immunomodulatory and antitumor efficacy in preclinical models, including in vivo studies of KRAS-driven lung cancer, highlighting its utility in oncology and immunology research.

Research Area

Immunology & Inflammation, Metabolism Research, Signal Transduction

Key Properties

• CAS Number: 2456434-36-7
• MW: 382.54
• Purity: 99.04% (May vary between batches)
• Formula: C₂₄H₃₄N₂O₂
• SMILES: N(CC(C)C)(C1=CC(C(C)(C)C)=CC(C(C)(C)C)=C1)C2=CC=C(C(O)=O)C=N2
• Target: Kras,NOS,Lipid,NO Synthase,ERK,Retinoid Receptor,Ras
• Solubility: DMSO:45 mg/mL (117.63 mM)

Bioactivity

• Target IC50:
  iNOS:158 nM
• In Vivo:
  MSU-42011 (25 mg/kg; oral; for 12 weeks) significantly reduced the number, size, and overall tumor burden of tumors in the A/J mouse lung cancer model. Compared with the control group, there were fewer cells with active proliferation and showed a significant decrease in p-ERK . MSU-42011 (25 mg/kg; oral; single dose) is most effective in reducing the number, size, and overall tumor burden of the A/J mouse lung cancer model in combination with C/P. Reduced macrophages in the lungs and increased activation markers of CD8+T cells . MSU42011 (100 mg/kg; PO; single dose) reduces tumor burden in a mouse lung tumor model .
  Read more...
• In Vitro:
  MSU-42011 (300 nM; 8 h) showed a low induction effect on SREBP in HepG2 cells. MSU-42011 (0-5000 nM; 24 h) can activate RXR in HepG2 cells.

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

6((3,5ditertbutylphenyl)(isobutyl)amino)nicotinicacid, Inos, MSU 42011, MSU42011, MSU-42011, NOSynthase, NO Synthase, Retinoid Receptor, RetinoidReceptor, SREBP, RXR, PERK

Compound Identifiers

PubChem CID

154656181